Debiopharm Joins Discussions With International Health Organisations to Fight Anti-Microbial Resistance at the 2023 World AMR Congress
6.9.2023 15:00:00 EEST | Business Wire | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.
Debiopharm’s panelist Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, is part of the AMR preparedness keynote panel to be moderated by Bruce Y. Lee from Forbes and involving representatives from the CDC, Menarini Group, IFPMA and the AMR Action Fund. A further Debiopharm-sponsored breakout session, moderated by Dr. Ricardo Chaves, Executive Medical Director, will feature Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC, explaining the relevance of novel microbiome-sparing antibiotics in combating AMR, and the potential need for new regulatory approval and reimbursement pathways.*
“It’s important to harness these open dialogues between public organizations and the infectious disease industry experts at World AMR to produce action that can prepare us to face the emerging wave of resistant infections,” explained Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm. “We know that uncontrollable infectious diseases are everybody’s business, and that our preparation efforts must involve the reinforcement of prevention measures, better stewardship education, and sustainable market pathways for new effective treatments.”
“The CDC recognizes the importance of the human microbiome as it provides key resistance to human colonization with multidrug-resistant pathogens. Along with products that will reduce the degree of colonization (i.e. pathogen reduction), or drugs that will restore the microbiome, we need therapeutic antibiotics that spare the microbiome, by being highly-selective for only specific pathogens.” expressed Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC.
Last year’s special report from the CDC on the impact of COVID-19 on antimicrobial resistance revealed that 6 of the 18 most alarming bacterial menaces cost the US more that $4.6 billion each year and thousands of human lives.4 The agency’s 18 bacterial and fungal threats include 2 pathogens for which Debiopharm is currently developing new antibiotics: Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus. Debiopharm’s FabI inhibitor therapies are part of a new pathogen-specific antibiotic class that is being researched for its capacity to effectively treat a single type of bacteria and thereby preserve the microbiome and avoid subsequent spread of AMR.
|
World AMR 2023 Session details |
Congress agenda |
Speakers |
|
Keynote panel Sept. 7th 08:35 EST
|
How can we push AMR to the forefront of preparedness? |
Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm + other invited speakers
|
|
Panel discussion Sept. 7th 11:00–11:30 EST
|
Antibiotic Development stream
The public health case for microbiome-sparing antibiotics: Potential need for new pathways in regulatory approval and reimbursement
|
Moderator:
Executive Medical Director Debiopharm
Speaker: Dr.L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC
|
About afabicin
Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor against Staphylococcus spp., whose methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or IV and selectively targets Staphylococcus ’ essential bacterial fatty acid biosynthesis. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a Phase 2 trial in bone and joint infections is being conducted in several countries comparing afabicin to standard antibiotics.
About Debio 1453
Analogous to afabicin, the preclinical compound Debio 1453 is a potential first in class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 is administered orally to treat Neisseria gonorrhoeae , the bacteria causing the sexually transmitted disease gonorrhea, a cause of serious and permanent health issues including infertility, ectopic pregnancy, cardiovascular and neurological problems.
Debiopharm’s fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci, being the most clinically advanced for the treatment of bone and joint infections. As a result of high selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota and meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
References
[1] Morrison L, Zembower TR. Antimicrobial resistance. Gastrointest Endosc Clin N Am. 2020 Oct;30(4):619-635.
[2] Antimicrobial resistance surveillance in Europe 2023–2021 data. www.who.int/europe/publications/i/item/9789289058537
[3] CDC Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
[4] COVID-19 U.S. Impact on Antimicrobial Resistance. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf
Disclosures
* Speaker disclosures: Dr. McDonald has no relevant financial or non-financial relationships to disclose. The findings and conclusions of this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. Any use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906072351/en/
Contact information
Debiopharm Contact
Dawn Bonine
Head of Communication
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO24.6.2026 10:05:00 EEST | Press release
In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda’s Representative Director, President and Chief Executive Officer. During the 150th Annual General Meeting of Shareholders, which took place in Osaka, Japan, shareholders elected Julie as a new internal director to the Board of Directors. Following the vote and conclusion of the meeting, the Board of Directors appointed her as Representative Director, President & CEO. Upon conclusion of the meeting, former president & CEO Christophe Weber retired from the Company and the Board. Chair of the Board of Directors Meeting, Masami Iijima, commented: “On behalf of Takeda’s Board of Directors, I would like to congratulate Julie Kim on becoming Takeda’s President and CEO. The Board of Directors is confident in Ms. Kim to drive executional excellence as Takeda launches a number of highly anticipated medicines and grows long-term shareholder value. The Board
Over Half of Consumers Will Pay More for Brands That Are Transparent About AI Data Use, New Usercentrics Research Finds24.6.2026 09:30:00 EEST | Press release
AI transparency has become a commercial differentiator, and it's reshaping where brand revenue is won — or lost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623804294/en/ Over half (52%) of consumers globally will pay more for brands that are transparent about how they use AI with their data at an average 7% premium. In Germany, that figure rises to 73% of consumers willing to pay a 9% premium, the highest of any market. The finding comes from the second annual State of Digital Trust 2026 Report, commissioned by Usercentrics, a leading data privacy technology company, and conducted by Sapio Research across 11,000 consumers in seven markets. The opportunity for brands that act is matched by the cost of inaction. Almost half (47%) of consumers surveyed have taken at least one action with a direct revenue consequence in the past six months because of concerns about how their data was being used in AI — canceling a subscri
LTM Joins Athena, a Chainguard-led Industry Coalition to Help Secure Open Source Software in the AI Era24.6.2026 09:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has joined Athena, a new industry coalition led by Chainguard, focused on protecting open source software from the rising threat of AI-driven vulnerabilities. Athena brings together leading organizations across the global software ecosystem to address an urgent challenge. As frontier AI models advance, they are increasingly capable of identifying novel vulnerabilities in open source software at machine speed, often faster than traditional disclosure and patching processes can respond. As AI accelerates both software development and the discovery of vulnerabilities, the window between a flaw being identified and being exploited has narrowed sharply. Athena is designed to close this gap through shared intelligence, coordinated action, and pre-disclosure remediation across the ecosystem. The coalition supports vulnerability management end to end, from discovery and analysis to patching, layered mitigations, and upstr
Ilkari Expands European Sovereign Infrastructure Operations With Integration of DC North in Croatia24.6.2026 09:00:00 EEST | Press release
Ilkari, a multinational sovereign infrastructure provider, today announced the integration of DC North in Croatia into its European operations, expanding its sovereign infrastructure footprint across the European Union and strengthening its multi-region platform, which includes existing operations in Iceland and Colombia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615555566/en/ DC North in Varaždin, Croatia, is now part of Ilkari’s expanding European sovereign infrastructure operations. The addition marks another step in Ilkari's ongoing build-out of EU-based sovereign infrastructure, as the company continues to scale its operational presence across regulated and sovereignty-focused markets. DC North becomes part of Ilkari's broader infrastructure ecosystem, which integrates domain services, colocation and sovereign cloud into a unified end-to-end stack spanning digital identity, infrastructure delivery and sovereign
Tigo Energy Predict+ Forecasting Platform Helps YASNO Keep Energy Flowing in Ukraine24.6.2026 07:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that Ukrainian electric utility, YASNO, is the latest enterprise-tier customer to deploy the Tigo Predict+ platform. The AI Energy platform empowers utility operators to adapt to real-world demand challenges as they balance renewable and baseload generation sources. Predict+ currently manages more than 650 GWh and delivers 97.5% forecast accuracy for utility customers. As the leading provider of electricity, gas, and energy-efficiency solutions in Ukraine, YASNO serves more than 2.5 million households in the Kyiv, Dnipropetrovsk, and Donetsk regions, as well as more than 64,000 business customers. YASNO uses the Predict+ platform in ways that go far beyond typical utility use cases, leveraging Tigo neural network-based AI to maintain grid stability amid highly variable weather and unpredictable infrastructure damage. The roll-out of Predict+ by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom